Kyverna Therapeutics, Inc. (KYTX)
Nasdaq: KYTX · Biological Products, (No Diagnostic Substances) · Emeryville, CA · filing with the SEC since 2023
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Mar 26, 2026 | Mar 27, 2025 | Mar 26, 2024 |
| Research and development | 133,720 | 112,473 | 49,923 |
| General and administrative | 36,107 | 30,131 | 12,483 |
| Total operating expenses | 169,827 | 142,604 | 62,406 |
| Operating income | -169,827 | -142,604 | -62,406 |
| Interest expense | 489 | 142 | 187 |
| Interest and investment income | 9,094 | 15,359 | 2,282 |
| Other income (expense), net | -85 | -90 | -55 |
| Total non-operating income (expense) | 8,520 | 15,127 | 2,040 |
| Income tax expense | 0 | 0 | 0 |
| Net income | -161,307 | -127,477 | -60,366 |
| Earnings per share, basic | -3.64 | -3.33 | -89.61 |
| Earnings per share, diluted | -3.64 | -3.33 | -89.61 |
| Weighted average shares, basic | 44,259,999 | 38,334,571 | 673,622 |
| Weighted average shares, diluted | 44,259,999 | 38,334,571 | 673,622 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding